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1. Introduction 
Dendritic cells (DCs) are well known for their capacity to induce adaptive antitumor 
immune response through their unique ability to uptake, processing and presenting 
antigens (Ags), and tumor-specific T cell activation. In addition, cytokines produced by 
dendritic cells are able to regulate the direction and strength of immune response, activate 
the cytotoxic cells (NK-, NKT-cells) and participate in the coordination of the humoral 
immune response (Melief, 2008; Banchereau et al., 2000). 
An increasing number of reports evidenced that besides this role, DCs may display 
additional antitumor effects. Indeed, DCs in vitro can inhibit proliferation and provide a 
direct cytotoxic effect on tumor cells. In this, human monocyte-derived DCs might exert 
antitumor activity through multiple TNF family members (i.e. TNF-ǂ, lymphotoxin-ǂ1ǃ2, 
FasL, TRAIL), as well as perforin and/or granzyme (Wesa & Storkus, 2008; Chauvin & 
Josien, 2008). 
Direct tumor cell killing by DCs themselves appear to be highly important since involves 
immediate presentation of tumor-associated Ags in the context of MHC molecules for 
recognition by cognate T cells, inducing a specific immune response. Importantly, 
pleiotropy in DC mechanisms of cytotoxicity allows DCs to overcome the resistance of 
tumor cells that are heterogeneous with regard to their sensitivity to the various death 
pathways. A number of evidence suggests that the direct antitumor effect of DCs is not 
purely in vitro phenomenon, and is implemented in vivo. First, DCs are present in the 
tumors, and their higher content correlates with a more favorable prognosis (Becker 1999). 
Second, intra-tumoral injection of intact DC (not loaded with tumor antigen) has been 
shown to correlate with reduced tumor growth and even regression (Becker et al., 2001; 
Ehtesham et al., 2003). Finally, it is shown that the intra-tumoral introduction of DCs 
improves the effectiveness of chemotherapy, which may be due to synergistic effects of 
cytostatics and DCs (Vanderheyde et al., 2004). 
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Most studies on antitumor activity of DCs in humans were performed with myeloid DCs 
isolated from peripheral blood or generate in vitro from peripheral blood monocytes in the 
presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 
(IL-4). Cytotoxic activity of these DCs was found to be stronger after treatment with type I 
interferons (IFN) or IFNǄ (Liu et al., 2001; Fanger et al., 1999). More recently, monocyte-
derived DCs generated in the presence of GM-CSF and IFNǂ instead of IL-4 were described. 
Is also known that IFNǂ-DCs are characterized by a higher expression of some molecules 
(TRAIL, FasL), which may mediate the cytotoxic/cytostatic activity of DCs (Chauvin & 
Josien, 2008). Indeed, we have demonstrated that LPS-activated IFNǂ-DCs inhibit the 
growth of tumor cell line HEp-2 more efficiently than IL4-DCs (Leplina et al., 2010). 
However, the antitumor potential of DCs generated in the presence of IFNǂ, remain 
virtually unexplored. 
Of great relevance is also an issue on safety of DC cytotoxic activity in cancer settings. 
Recently, we found that in patients with malignant gliomas IFNǂ-DCs generated in vitro are 
able to activate Th1 cells and induce an antitumor immune response (Leplina et al., 2007a). 
Nevertheless, these DCs exhibit several phenotypic and functional features, such as the 
moderate delay of differentiation/maturation and low capacity to induce the IFNǄ-
producing T-cells in mixt lymphocyte culture (MLC) (Leplina et al., 2007b). Given the data 
on the development of immune insufficiency and monocyte dysfunctions in patients with 
malignant brain tumors (Khonina et al., 2002) the study of various functions of DCs in this 
pathology is important not only in terms of understanding pathogenesis of the disease, but 
also to rationale the therapy with dendritic cells. In this article we investigated the cytotoxic 
potential of human monocyte-derived DCs generated under replacement of IL-4 with IFNǂ, 
and compared cytostatic/cytotoxic activities of IFNǂ-induced DCs in healthy donors and 
patients with brain tumors. 
2. The text of the article 
2.1 Materials and methods 
2.1.1 Patients 
The study was held in 32 healthy volunteers and 37 patients with brain tumors (21 men and 
16 women; from 21 to 71 years; median age 37 years). Patients’ group included 20 patients 
with histologically verified gliblastoma (Grade IV), 8 - with astrocytoma (Grade III) and 9 - 
with angioreticuloma, fibrilyarno-protoplasmic astrocytoma or meningioma (Grade I-II). All 
studies were performed after receiving a written informed consent.  
2.1.2 In vitro differentiation and maturation of DCs 
Peripheral blood mononuclear cells (MNCs) were obtained by density gradient 
centrifugation (Ficoll-Paque, Sigma-Aldrich) of heparinized whole blood samples. Dendritic 
cells were generated by culturing of plastic-adherent MNC fraction in 6-well plates 
(Nunclon, Denmark) in RPMI-1640 medium (Sigma-Aldrich), supplemented with 0,3 
mg/ml L-glutamine, 5 mM HEPES buffer, 100 µg/ml gentamicin and 5% fetal calf serum 
(FCS, Sigma-Aldrich), in the presence of recombinant human (rh) GM-CSF (40 ng/ml, 
Sigma-Aldrich) and rhIFN-ǂ (Roferon-A, 1000 U/ml, Roche, Switzerland) for 4 days (IFNǂ-
DCs) or with rhGM-CSF (40 ng/ml) and IL-4 (40 ng/ml, Sigma-Aldrich) for 5 days ( IL4-
DCs). The resulting immature DCs were further exposed with 10 µg/ml lipopolysaccharide 
(LPS E.colli 0114: B4, Sigma-Aldrich) into IFNǂ-DC and IL4-DC cultures for additional 24h 
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and 48h, respectively. For some experiments DC supernatans generated from LPS-activated 
IFNǂ-DCs were collected. The viability of obtained IFNǂ–DCs or IL4–DCs determined by 
Trypan blue exclusion was more than 93-95% in all cases. 
2.1.3 Cell lines 
Tumor cell lines used in this study included leukemia cell line Jurkat (T- lymphoblast cell 
leukemia) and solid tumor-derived cell lines: epithelial cells of human larynx carcinoma 
HEp-2 and glioblastoma U-87 were purchased from American Type Culture Collection 
(Manassas, VA). All cell lines were of human origin, mycoplasma free and were grown 
under standard cell culture conditions.  
2.1.4 Cytotoxicity assay 
Generated IFNǂ–DCs were tested for their cytotoxic activity against various tumor cell lines 
including Jurkat, HEp-2 and U-87. Before coculture, target cells were labeled with 
[3H]thymidine (1 µCi/well) for 18 h at 37°C, washed and placed at 104/well in 96-well tissue 
culture plates in RPMI-1640 medium containing 10% FCS. Cell-free supernatants from DC 
cultures (30%, v/v) or different numbers of effector cells (DCs) were added to tumor cells at 
effector:target (E:T) ratios of 10:1, 20:1 and 40:1. In some experiments DCs were pre-
incubated for 1 h with the following fusion proteins: rhTNFR1/TNFRSF1A Fc chimera (10 
μg/ml), rhFas/TNFRSF6/CD95 Fc chimera (10 μg/ml), and rhTRAIL R2/TNFRSF10B Fc 
chimera (10 μg/ml; all reagents from R & D Systems, USA). After 18 h of culture cells were 
harvested and thymidine incorporation was measured on a Liquid Scintillation beta-
Counter (Packard Instrument, Meriden, CT). Percentage of cytotoxicity was calculated by 
the formula:  
[1 - (cpm in cocultures of tumor and effector cells or DC supernatans/ cpm in tumor cell 
cultures)] x 100%. 
2.1.5 Cytostatic assay 
Cytostatic activity of DCs was evaluated by their ability to suppress the proliferation of 
tumor line cells (HEp-2 and U-87). For this, the target cells (103/well) were incubated for 48 
h in 96-well plates alone and in the presence of effector cells at E:T ratios about 10:1, 20:1 and 
40:1. Cell proliferation was measured by [3H]thymidine incorporation (1 μCi/well for last 24 
h). The percentage of cytostatic activity was calculated by the formula:  
[1 - (cpm in cultures with effector cells / cpm in control cultures)] x 100%. 
2.1.6 Apoptosis detection 
To determine the level of apoptosis, HEp-2 tumor cells were preliminary stained with vital 
dye CFSE (2 mM, Molecular probes, USA) for 15 min, then washed in RPMI-1640/10% FCS 
and incubated in 96-well tissue culture plates (104/well) in the presence of IFNǂ-DCs at a 
ratio 10:1 for 18 hours. The number of cell divisions was analyzed by flow cytometry (FACS 
Calibur, Becton Dickinson, USA) on channel FL1 (CFSE fluorescence) with the emission of 
517 nm. The level of apoptosis was detected by DNA intercalating dye 7-AAD (Calboichem, 
Israel). Results were expressed as a percentage of positive cells to the total cell number in the 
region studied. 
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2.1.7 TNFα production 
DC-free supernatants collected as deascribe above were measured for soluble TNFǂ by 
ELISA using a commercial kit (R & D Systems, USA) according to the manufacturer`s 
recommendations. 
2.1.8 Statistical analysis 
The data were expressed as mean ± SE. Statistica 6.0 software for Windows (StatSoft Inc. 
USA) was used for analysis of data. Statistical comparisons were performed using the 
nonparametric Mann-Whitney U test. P-values < 0,05 indicate significant differences. 
2.2 Results 
2.2.1 Cytotoxic activity of donor IFNα-DCs and DC supernatants against tumor cell 
lines  
First, we assessed whether in vitro generated mature IFNǂ-DCs could lyse tumor cell lines. 
IFNǂ-DCs in our study possessed significant dose-dependent cytotoxic activity against 
[3Н]thymidine-labeled tumor cell lines HЕp-2 and Jurkat. As illustrated in Fig.1A, Jurkat 
cells were lysed more efficiently at all E:T cell ratios. The most pronounced differences in 
cytotoxic activity of IFNǂ-DCs against Jurkat and HEp-2 were observed at a E:T ratio of 20:1 
(35,17 ± 5,6% and 16,44 ± 4,01 %, respectively; PU=0,027). High cytotoxic activity of IFNǂ-
DCs was also manifested when human glioblastoma U-87 cells were used as targets (Fig.1B). 
In this case, the cytotoxic potential of DCs at 20:1 was two-fold higher than with HEp-2 cells 
(38,6 ± 8,3%; PU=0,049). Taken together, these data indicate that i) mature IFNǂ-DCs 
mediated significant antitumor cytotoxic activity, effective at various E:T cell ratios, and ii) 
the cytotoxic activity of IFNǂ-DCs against tumor cell lines Jurkat and U-87 unlike HEp-2 
cells was considerably higher. 
 
 
 
Fig. 1. Cytotoxic activity of donor IFNǂ-DCs against Jurkat, Hep-2, and U-87. A) The 
average values of IFNǂ-DC cytotoxic activity against tumor cell lines Jurkat and HEp-2 are 
presented. Effector cells (DCs) and [3H]thymidine-labeled target cells (Jurkat and HEp-2) 
were cultured for 18 h at ratios indicated. B) Cytotoxic activity of IFNǂ-DCs against Jurkat, 
HEp-2 and U-87 tumor cells at E:T ratio of 20:1. Results are shown as mean ± SE of triplicate 
values. * - PU <0,05 - between HEp-2 and Jurkat at E:T ratio of 20:1 (U - Wilcoxon's test, 
Mann-Whitney).  
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To examine the possible mechanisms underlying the cytotoxic activity of IFNǂ-DCs against 
tumor cells, we evaluated the cytotoxic activity associated with DC culture-conditioned 
medium. Contrary to DCs themselves, IFNǂ-DC culture-conditioned medium lacked 
cytotoxic activity or had a low ability to lyse tumor cells. Indeed, supernatants of DC 
cultures added to targets at 30% (v/v) were unable to lyse HEp-2 cells, and had some 
cytotoxic activity against Jurkat cell line (13,0 ± 1,7%) (Fig.2). These results showed that 
mediators of DC-associated antitumor activity are more likely cell membrane-bound 
molecules but not secreted proteins. 
2.2.2 Induction of apoptosis of tumor cell line HEp-2 by IFNα-DCs 
To investigate whether DC killer activity involved the induction of apoptosis, we next 
analyzed cell cycle in tumor cells HEp-2 pre-labeled with vital dye CFSE (Fig.3). Co-
culturing of CFSE-labeled HEp-2 cells with IFNǂ-DCs resulted in significant increase in the 
level of apoptosis detected in tumor cells. In addition, the cultivation of tumor cells with 
IFNǂ-DCs was accompanied by a decrease in number of cycling tumor cells (S + G2M 
phases of the cell cycle). These results showed that DCs in vitro can efficiently induce death 
of tumor cells using an apoptotic mechanism. 
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Fig. 2. Cytotoxic activity of DC culture-conditioned medium against Jurkat and HEp-2. The 
figure represents individual values of cytotoxic activity mediated by supernatants from 
cultures of healthy donor IFNǂ-DCs against tumor cell lines HEp-2 (n = 17) and Jurkat  
(n = 6). Jurkat cells and HEp-2 cells (104cells/well) were labeled with [3H]thymidine and 
incubated with DC culture-conditioned medium (30%, v/v) for 18 hours.  
2.2.3 Growth inhibition effect of IFNα-DCs on tumor cell lines HEp-2 and U-87 
These data result in the suggestion that the cytotoxic activity of IFNǂ-DCs is conditioned by 
induction of apoptosis in tumor cells and that, along with a cytotoxic effect, IFNǂ-DCs 
apparently could block cell cycle in tumor cells, thereby providing cytostatic effect. Indeed, 
analysis of IFNǂ-DCs impact on the proliferation of tumor cells (Fig. 4) revealed a 
pronounced antiproliferative effect exerted by donor DCs against the cell line HEp-2.  
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Fig. 3. Effect of IFNǂ-DCs from healthy donors on the cell cycle in HEp-2. The figure shows 
the relative content (%) of CFSE-labeled HEp-2 cells in cell cycle phases in the absence of 
DCs (control; n= 4) and in co-cultures with IFNa-DCs (n= 4) for 18 hours at E:T ratio of 10:1. 
The data are presented as M ± SE (%). * - PU<0,01 (U - Wilcoxon's test, Mann-Whitney).  
 
 
Fig. 4. Tumor-inhibiting activity of IFNǂ-DCs from healthy donors against НЕȞ-2, Jurkat, 
and U-87. А) The graph shows the mean values (M ± SE) of cytostatic activity of IFNǂ-DCs 
against HEp-2 tumor cells (n = 8). Effector cells (DC) and target cells were cultured at ratios 
indicated for 24 hours, followed by the introduction of [3H]thymidine for 24 hours. B) 
Cytostatic activity rendered by IFNǂ-DCs against HEp-2 (n = 8), Jurkat (n = 7) and U-87  
(n = 5) in E:T ratio of 20:1. * - PU <0,05 - between the cytostatic activity of DCs vs HEp-2 and 
U-87 (U - Wilcoxon's test, Mann-Whitney). 
Importantly, DCs mediated potent inhibitory activity (45,4 ± 6,24%) even at a low E:T cell 
ratio (10:1). Moreover, IFNǂ-DCs also suppressed the proliferation of glioblastoma cell 
line U-87. However, in this case inhibition was almost two-fold lower, accounting for 27,4 
± 4,4% at E:T ratio of 20:1 vs 52,4 ± 4,4% in HEp-2 cultures (p <0,05). Thus, in our study 
IFNǂ-DCs were found to be cytostatic for tumor cell lines. Comparative analysis of 
cytotoxic and cytostatic activity mediated by IFNǂ-DCs showed no correlations between 
the level of DC cytotoxicity and their ability to inhibit the proliferation of HEp2 (rS = 0,21; 
p = 0,7), U-87 (rS = 0,5; p = 0,28) and Jurkat (rS = 0,33; p = 0,5) tumor cell line. The lack of 
such a relationship was also indicated by the fact that in cultures of U-87 dendritic cells 
displayed the highest cytotoxic effect while their cytostatic effects were only moderate. 
Contrary, in cultures of HEp-2 DCs had a relatively low cytotoxic effect and pronounced 
anti-proliferative activity. 
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2.2.4 Role of TNFα, FasL and TRAIL in cytotoxic activity of IFNα-DCs 
To get inside into the mechanism that could be responsible for DC tumoricidal activity, we 
have investigated the role of key molecules involved in the apoptosis pathway. Cytotoxic 
activity of DCs is attributed to the expression of some proapoptotic molecules such as 
TRAIL, FasL, perforin, granzymes A and B, TNF-ǂ, lymphotoxin-ǂ1, ǃ2 (Chauvin & Josien, 
2008). To further characterized the molecular mechanisms by which HEp-2 cell death results 
from interaction with DCs, we studied the effect of some soluble receptors at the DC-
mediated cytotoxic activity. As evident from Fig. 5, pretreatment of IFNǂ-DCs with TNFR1: 
Fc resulted in almost complete neutralization of DC cytotoxic activity, whereas pretreatment 
with soluble forms of TRAIL-R2: Fc and Fas: Fc did not followed by suppression of DC killer 
activity.  
 
 
Fig. 5. Neutralization of DC cytotoxic function by soluble forms of R:Fc, specific for TNF-
family ligands. [3H]thymidine-labeled tumor cells HEp-2 (104 cells/well) were incubated for 
18 hours with IFNǂ-DCs (at E:T ratio of 20:1) pre-treated for 1 h with TRAIL-R2: Fc fusion 
protein (10 μg/ml; n = 6), or TNFR1: Fc fusion protein (10 μg/ml; n = 6), or Fas: Fc fusion 
protein (10 μg/ml; n = 6). Data are presented as mean (M ± SE) of cytotoxic activity of IFNǂ-
DCs vs HEp-2. * - PU <0,01 - between intact DCs and DCs treated with TNFR1: Fc (U - 
Wilcoxon's test, Mann-Whitney). 
Thus, our data suggest that lysis of HEp-2 cells is not related with TRAIL- and FasL-mediated 
cytotoxicity but occurs with the involvement of TNFǂ molecules, since blocking of 
TNFǂ/TNFR1 binding leads to almost full suppression of DC killer activity. Apparently, the 
involvement only a single of three described mechanisms of DC cytotoxicity is due to 
resistance of tumor cells HEp-2 to TRAIL-and FasL-mediated apoptosis and determines 
relatively low cytotoxic activity of DCs against HEp-2 cells compared to Jurkat and U-87 which 
are sensitive to FasL-and TRAIL-mediated apoptosis (Röhn et al., 2001; Hoves et al., 2003). 
2.2.5 Cytotoxic activity of donor IL4-DCs in compared with IFNα-DCs 
Since we proposed IFNǂ-DCs may have a more pronounced antitumor activity than DCs 
generated with GM-CSF and IL-4, we then investigated whether cytotoxic and cytostatic 
activities of these two types of LPS-activated DC were distinct. As seen in Fig.6, IFNǂ-DCs 
possessed the higher ability to lyse leukemia cells Jurkat (Fig. 6A) and comparable cytotoxic 
activity in HEp-2 cultures (Fig.6B). However, IFNǂ-DCs were found to be more effective in 
suppressing the growth of tumor cell line HEp-2 than IL4-DCs (45 ± 6% vs 29 ± 7%, 
respectively, at E:T ratio of 10:1, PU <0,05). 
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Fig. 6. Cytotoxic activity of IFNǂ-DCs and IL4-DCs of healthy donors against tumor lines 
Jurkat (A) and HEp-2 (B). Data are presented as mean (M ± SE) of cytotoxic activity. Effector 
cells (donor IFNǂ-DCs and IL4-DCs) were incubated with target cells ([3H]thymidine-
labeled tumor cell lines Jurkat and HEp-2) at ratios indicated for 18 h. *- РU<0,05 – between 
IFNǂ-DCs and IL4-DCs against Jurkat (U - Wilcoxon's test, Mann-Whitney).  
2.2.6 Cytotoxic activity of patient IFNα-DCs vs HEp-2  
While donor DCs were found to be tumoricidal, evaluation of the cytotoxic activity of DCs 
generated in vitro from peripheral blood of brain glioma patients revealed they were 
significantly less cytotoxic against HEp-2 cells (Fig.7A). The decrease of cytotoxic activity 
was manifested at all E:T ratios which were analyzed. At the same time assessment of 
patient DC killer activity at E:T ratio of 20:1 (n=37) allowed to reveal significant 
heterogeneity for DC cytotoxic potential in patients with brain tumors (Fig.7B). Indeed, in 25 
patients (67%) cytotoxic activity was completely absent, whereas remained relatively 
unaltered in another 12 patients (32%). 
 
 
Fig. 7. Cytotoxic activity of IFNǂ-DCs of patients with brain tumors against HEp-2. A) Effector 
cells (donor and patient IFNǂ-DCs) were cultured with [3H]thymidine-labeled target cells 
(HEp-2) for 18 h at ratios indicated. Results are shown as the mean ± SE of DC cytotoxic 
activity. *- PU <0,01 - between donor and patient DCs (U - Wilcoxon's test, Mann-Whitney) at 
E:T ratio of 40:1 and 20:1. B) Individual values of cytotoxic activity mediated by IFNǂ-DCs of 
healthy donors and brain tumor patients against HEp-2 are presented. Effector cells (DC) were 
cultured with [3H]thymidine-labeled target cells (HEp-2) for 18 h at ratio of 20:1.  
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Analysis of patients according to the degree of tumor malignancy demonstrated that the 
decrease in cytotoxic activity of DCs was typical for patients with high grade (III-IV) 
gliomas while patients with low grade (I-II) intracerebral gliomas were characterized by 
unaltered cytotoxic activity (Table 1). 
 
E:T ratio = 20:1 Donors (n=22) Patients with brain tumors 
Grade I-II (n=9) Grade III-IV (n=28) 
M ± S.E 21,5 ± 2,6 22,56 ± 5,64  4,75 ± 1,95  
Median 17,0 20,0 0 
LQ-UQ 10,3- 32,0 13,0- 29,0 0- 4,0 
Table 1. Cytotoxic activity of IFNǂ-DCs in patients with low and high grade glioma 
Effector cells (IFNǂ-DCs) were generated from peripheral blood of healthy donors and 
patients with low grade (I-II) and high grade (III-IV) gliomas and cultured with 
[3H]thymidine-labeled target cells (HEp-2) for 18 h at E:T ratio of 20:1. The average values 
(M ± SE), Median and interquartile range (from low to upper quartile, LQ-UQ) of cytotoxic 
activity are presented. 
Figure 8 shows the individual examples of cytotoxic activity of IFNǂ-DCs of patients with 
Grade I-II (n=3) and III-IV (n=3) brain tumors. 
2.2.7 Survival rates of patients with intact and reduced levels of IFNα-DC cytotoxic 
activity vs HEp-2 cells 
Considering that the degree of malignancy is predictive factor of patient survival, we further 
questioned about the survival rates of patients with intact and reduced levels of DC 
cytotoxic activity against HEp-2 cells (Fig. 9). The criterion for division into such groups was 
the lower quartile range of cytotoxic activity mediated by donor IFNǂ-DCs against HEp-2 
cells (LQ=10,3%).  
Patients with decreased cytotoxic activity of IFNǂ-DCs (< 10,3%, 1 patient with Grade II and 
15 patients with Grade III-IV) differed by a lower survival rate compared with patients of 
the opposite group. For example, a median of survival in patients with low DC cytotoxic 
activity was about 13 months, and in the group with unchanged cytotoxic activity of DCs all 
patients (5 patients with Grade I-II and 4 patients with Grade III) were followed alive. 
2.2.8 Growth inhibition effect of patient IFNα-DCs on tumor cell line HEp-2  
Next, we investigated whether DCs of patients with brain tumors could inhibit the growth 
of HEp-2 cells (Table 2). While donor DCs possessed the marked cytostatic activity, IFNǂ-
DCs of patients with intracerebral gliomas were found to be incapable of suppressing the 
proliferation of HEp-2. Moreover, the addition of DCs led to 3-fold increased tumor cell 
proliferation. The index of DC impact ranged from 0,5 to 7,2, averaging about 3,06± 0,4. It 
should be noted that such a stimulatory effect of DCs on HEp-2 cell growth was detected 
both in patients with high grade III-IV (3,08 ± 0,65; n = 19) and low grade I-II (3,37 ± 1,49;  
n = 8) tumors, and unlike cytotoxic activity, was independent on the degree of malignancy. 
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Fig. 8. Cytotoxic activity of IFNǂ-DCs of individual patients. Figure represents the 
individual values of cytotoxic activity of IFNǂ-DCs generated in vitro from peripheral blood 
of tumor patients against HEp-2. Effector cells (DCs) and [3H]thymidine-labeled HEp-2 cells 
were co-cultured for 18 h at ratios indicated. Percentage of cytotoxicity was calculated as 
follows: [1 - (cpm in cultures with target and effector cells / cpm in control cultures without 
effector cells)] x 100%. 
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Fig. 9. Survival rates of patients with brain tumors based on the level of DC cytotoxic 
activity. Dotted line: cytotoxic activity of DCs of patients is below (<10,3%) donor lower 
quartile values. Solid line: cytotoxic activity of patient DCs is above 10,3%. 
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The table represents the individual values of indexes of IFNǂ-DC impact on proliferation of 
tumor cell line HEp-2. For this, effector cells (DCs) and targets were cultured at 20:1 for 24 
hours, followed by the introduction of [3H]thymidine for the next 24 hours. The index of DC 
impact was calculated by the formula: cpm in cultures with target and effector cells / cpm in 
control cultures without effector cells. * - PU <0,01 between donors and patients (U - 
Wilcoxon's test, Mann-Whitney). 
 
Patients Diagnosis DC cytostatic activity 
(Indexes of DC impact) 
P 1, female, 60 years Grade 1 5,6 
Р 2, female, 71 years  Grade 1 6,2 
Р 3, male, 53 years  Grade 1 0,9 
P 4, female, 35 years  Grade 2 7,2 
Р 5, male, 42 years  Grade 2 3,4 
P 6, female, 38 years  Grade 2 0,8 
P 7, female, 36 years Grade 2 0,5 
P 8, female, 35 years  Grade 2 0,5 
M±SE (n=8)  3,37 ± 1,49 
Р 9, male, 56 years  Grade 3 5,0 
Р 10, male, 25 years  Grade 3 3,5 
Р 11, male, 46 years  Grade 3 0,5 
Р 12, male, 29 years  Grade 3 2,3 
P 13, female, 24 years  Grade 3 3,2 
Р 14, male, 32 years  Grade 4 3,1 
P 15, female, 54 years  Grade 4 5,2 
Р 16, male, 48 years  Grade 4 3,2 
Р 17, male, 53 years  Grade 4 2,4 
Р 18, male,41 years  Grade 4 2,4 
Р 19, male, 34 years  Grade 4 1,8 
Р 20, male, 24 years  Grade 4 1,4 
Р 21, male, 38 years  Grade 4 0,8 
Р 22, male,47 years  Grade 4 2,3 
P 23, female, 45 years  Grade 4 6,9 
P 24, female, 58 years  Grade 4 6,5 
P 25, female, 60 years  Grade 4 6,9 
P 26, female, 71 years  Grade 4 0,8 
P 27,female, 57 years  Grade 4 2,0 
 M±SE (n=19)  3,08 ± 0,645 
Patients (n=27)   3,06 ± 0,4* 
Healthy donors (n=14)   0,4 ± 0,04 
Table 2. Effect of IFNǂ-DCs of patients with brain tumors on the proliferation of HEp-2 cells 
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2.2.9 Cytotoxic activity of patient IFNα-DCs vs U-87 
In the next experiments, we investigated cytotoxic potential of patient IFNǂ-DCs towards 
TRAIL-sensitive tumor line U-87. Interestingly, we found no decrease in killer activity of 
patient DCs in this case. Furthermore, IFNǂ-DCs of patients with malignant tumors (Grade 
III-IV), unable to lyse HEp-2 cells, were highly cytotoxic against U-87 cells compared with 
healthy donors (Table 3). Further experiments demonstrated the ability of patient DCs to 
inhibit the proliferation of U-87 cell line which is also more expressed in patients than in 
donors (46,6 ± 7,5 and 27,4 ± 4,4%, respectively; РU< 0,01). In this, we found a strong positive 
correlation between cytotoxic and cytostatic activities (rS = 0,89; p = 0,001). Thus, 
impairment of cytotoxic and cytostatic activity of patient DCs was only revealed against 
HEp-2 cells. 
 
Patients Diagnosis DC cytotoxic 
activity (%) 
DC cytostatic 
activity (%) 
Р 1, male, 36 years Grade 4 76 54 
Р 2, male, 24 years Grade 4 55 28 
P 3, female,69 years Grade 4 39 40 
P 4, female, 42 years Grade 3 60 44 
P 5, female, 71 years Grade 3 57 40 
P 6, female, 54 years Grade 4 60 43 
P 7, female, 46 years Grade 4 56 12 
Р 8, male, 48 years Grade 4 80 89 
Р 9, male, 24 years Grade 3 69 69 
Patients (n=9)  61,3 ± 4,1* 46,6 ± 7,5* 
Healthy donors (n=5)  38,6 ± 8,3 27,4 ± 4,4 
Table 3. Cytotoxic/cytostatic activity of DCs in patients with brain tumors against U-87. The 
table represents the individual and average values (M ± SE) of cytotoxic and cytostatic 
activities of patient and donor DCs. Cytotoxicity was measured by coculturing of DCs and 
[3H]thymidine-labeled U-87 cells for 18 h at 20:1. For cytostatic activity evaluation, DCs and 
U-87 cells were cultured at 20:1 for 24 hours, followed by the introduction of [3H]thymidine 
for 24 hours. * - РU <0,01 between donors and patients (U - Wilcoxon's test, Mann-Whitney). 
2.2.10 TNFα production by donor and patient IFNα-DCs 
Since the cytotoxic activity of DCs against HEp-2 cells was related with TNF-mediated 
apoptosis, we further compared the ability of DCs of patients with malignant gliomas 
(Grade III-IV) and donors to produce TNFǂ. The concentration of TNFǂ was evaluated in 4-
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day cultures of LPS-activated IFNǂ-DCs. As follows from Table 4, supernatants from patient 
DC cultures differed little from healthy donor culture-conditioned medium by the level of 
TNFǂ production. A slight decrease in production of TNFǂ was a tendency, which had no 
statistical significance. 
 
Patients Diagnosis TNFa (pg/ml) 
P 1, male, 39 years  Grade 4 856 
P 2, female, 46 years Grade 3 767 
P 3, male, 35 years Grade 3 800 
P 4, male, 46 years  Grade 3 914 
P 5, male, 24 years Grade 4 918 
P 6, female, 43 years  Grade 4 693 
P 7, female, 38 years Grade 2 256 
P 8, male, 52 years Grade 4 486 
P 9, male, 68years  Grade 3 710 
Patients  
 (n=9)                  M ± SE  
 
711 ± 82 
Healthy donors 
 (n=11)                M ± SE  
 
824 ± 59 
Table 4. TNFǂ concentrations in cultures of donor and glioma patient IFNǂ-DCs. The table 
represents the individual and average values (M ± SE) of TNFǂ concentrations in culture 
supernatants of IFNǂ-DCs generated in vitro from peripheral blood of patients with 
malignant gliomas and healthy donors. 
2.3 Discussion 
The ability of DCs generated in vitro to inhibit the growth of human tumor cell lines and 
lyse tumor cells was first demonstrated by Chapoval (Chapoval et al., 2000). Thereafter, 
spontaneous cytotoxicity mediated by DCs without any stimulation was also described by 
other authors (Vanderheyde et al. 2004; Yang et al., 2001; Manna & Mohanakumar, 2002; Joo 
et al., 2002 ; Janjic et al., 2002), which revealed that the tumoricidal potential of DCs 
generated in the presence of GM-CSF and IL-4 was mediated by effector molecules such as 
FasL (Yang et al., 2001), TNF (Manna & Mohanakumar, 2002; Joo et al., 2002), lymphotoxin- 
ǂ1, ǃ2 (Lu et al., 2002) or TRAIL (Liu et al., 2001). The cytolytic properties of cultured human 
monocyte-derived DCs are enhanced by certain activation stimuli, such as LPS (Chapoval et 
al., 2000; Manna & Mohanakumar, 2002). While myeloid DCs being treated with IFN- 
exhibited upregulation of intracellular TRAIL and increased cytotoxic potential (Liu et al., 
2001), study of antitumor activity of DCs generated in the presence of IFNǂ were not 
performed previously. In this study, we reported the novel data on cytostatic/cytotoxic 
activities of LPS-activated IFNǂ-DCs generated in vitro from peripheral blood monocytes of 
healthy donors and patients with brain tumors. 
We report here that LPS-activated IFNǂ-DCs can lyse both NK-sensitive (Jurkat lymphoma 
cells) and NK-resistant (HEp-2, U-87) tumor cell lines. Such a cytotoxic effect requires cell 
contact, since the supernatants of IFNǂ-DCs either lack or possess the poor cytotoxic 
activity. Using HEp-2 tumor cells as targets, we revealed that DCs appear to promote the 
apoptosis and suppress cell cycle in tumor cells, thus having a cytostatic effect. Cytostatic 
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activity was also confirmed by the tumor growth/proliferation inhibiting capacity realized 
by IFNǂ-DCs. When compare the cytotoxicity of IFNǂ-DCs and IL4-DCs, we revealed that 
IFNǂ-DCs expressed the higher ability to kill Jurkat tumor cells as well as comparable with 
IL4-DCs cytotoxic activity in HEp-2 cultures.  
Since the highest cytotoxic activity of IFNǂ-DCs was manifested in U-87 and Jurkat tumor 
cell cultures, which are reported to be sensitive to TRAIL-induced apoptosis (Lee et al., 2003; 
Panner et al., 2005; Siegelin et al., 2009), it is reasonable to assume that this cytotoxicity could 
be due to the stimulative effect of IFNǂ on TRAIL expression (Riboldi et al., 2009). Indeed, 
as a further corroboration of the suggested cytotoxic capacity, our data demonstrated that 
LPS-activated IFNǂ-DCs were found to contain significantly higher amounts of cells 
expressing membrane-bound TRAIL compared with IL4-DCs (data not shown). Apparently, 
these data could also explain a higher cytotoxic activity of IFNǂ-DCs on Jurkat tumor cells. 
There are a very few data on sensitivity of HEp-2 cells to the cytotoxic effect of DCs 
mediated by TNF family molecules. The tumoricidal activity was not mediated by FasL/Fas 
or TRAIL/TRAILR2 systems, whereas TNFǂ/TNFR1 blocking completely abolished the 
ability of DCs to lyse HEp-2 cells. Thus, tumor cell line HEp-2 cells can be considered as 
resistant to FasL- and TRAIL-induced apoptosis, but sensitive to cytotoxicity triggered by 
TNFǂ/TNFR1 pathway. At that, the fact that anti–TNFǂ antibody almost completely 
decreased cytotoxicity, while DC culture-conditioned medium containing quite high 
concentrations of TNFǂ lacked lytic activity (Leplina et al., 2007b), further implies that 
membrane-bound, not the soluble form, of TNFǂ partially contributes to the effect. 
Our results are consistent with the reported data on TNFǂ expression by HEp-2 cells 
(Paland et al., 2008), as well as the resistance of this tumor cell line to FasL-induced 
apoptosis (Morton & Blaho, 2007). The lack of sensitivity HEp-2 cells to TRAIL/TRAILRII-
induced death explains the absence of distinction in the cytotoxic activity of IFNǂ-DCs and 
IL4-DCs against HEp-2 cells. 
Since we revealed no correlations between cytotoxic and cytostatic effects of IFNǂ-DCs on 
HEp-2 cells, then one can believe that cytotoxicity and cytostasis could be mediated by 
distinct mechanisms. Similar tendency was observed for IL4-DCs (Vanderheyde et al., 2004), 
where the authors have shown that LPS-stimulated IL4-DCs possess TNFǂ-associated 
cytostatic activity unrelated with cytotoxicity. Indeed, IL4-DCs inhibited the growth of 
modified Jurkat cells deficient in caspase-8 or overexpressing Bcl-2. On the other hand, 
supernatants of IL4-DCs suppressed the proliferation of non-modified Jurkat cells, but 
showed no cytotoxic activity. Evidently, cytostatic and cytotoxic activities of IFNǂ-DCs are 
also implemented through independent mechanisms. This hypothesis could be confirmed 
by the fact that a higher cytotoxic activity of IFNǂ-DCs against U-87 and Jurkat cells was 
associated with less pronounced DC cytostatic activity on these lines compared with HEp-2. 
Investigation of the effector functions of IFNǂ-DCs in patients with intracerebral gliomas 
revealed impaired ability of these cells to lyse HEp-2 tumor cells. Importantly, such an 
impairment of DC cytotoxicity was identified mainly in patients with high grade (III-IV) 
brain tumors, while in low grade (I-II) tumors DCs were quite effective killers. Furthermore, 
patients with intact DC cytotoxic activity had a higher survival rate than patients with 
reduced killer activity. In addition, patient DCs regardless of tumor histology showed no 
cytotoxic activity against HEp-2 cells, whereas both cytotoxic and cytostatic activities of DCs 
against U-87 cells were found to be enhanced. 
According to the data, glioblastoma cells U-87 are resistant to cytotoxicity mediated by 
TNFǂ (Sawada et al., 2004), and sensitive to TRAIL- (Knight et al., 2001) and Fas-induced 
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apoptosis (Choi et al., 2004). As we have found, DC cytotoxicity on HEp-2 cells likely 
engaged TNF/TNFR1 pathway than TRAIL or FasL effects. Given these facts, the high 
cytotoxic activity of patient DCs against U-87 cells and dramatic decline of such activity 
against HEp-2 tumor cells could indicate a defect in TNFǂ-related mechanism of DC 
cytotoxicity in patients with malignant gliomas. 
Our facts seemed to be important in several aspects. First, the defect in cytotoxic activity of 
DCs may be of interest in diagnosis and prognosis, since the expression of cytotoxic activity 
is associated with tumor malignancy and survival rates. Second, this phenomenon is of 
interest from the pathogenetic point of view. Malignant brain tumors induce a weak 
antigen-specific response due to tumor-induced immunosuppression, as well as localization 
of the tumor in the immunologically privileged brain tissues (Parney et al., 2000). We have 
previously shown that patient IFNǂ-DCs are characterized by intact antigen-presenting 
function, capable of activating T cells to produce Th1 cytokines and induce proliferation of T 
lymphocytes to antigens of tumor cell lysates (Chernykh et al., 2009). Then impairment of 
DC effector functions may inhibit the early induction of antigen-specific immune response 
being yet another reason for infringement of anti-tumor protection in patients with 
malignant brain tumors.  
We can also assume that if tumoricidal potential of DCs is disturbed, cytoreductive therapy 
(radio-chemotherapy) becomes especially important, both in regard of direct elimination of 
tumor cells and release of tumor antigens required to start specific immune response.  
However, whether IFNǂ-DCs could effectively destroy primary glioma cells and does this 
ability is disrupted in patients with malignant gliomas remains to find. Most of glioblastoma 
cell lines and primary cells gliomas are absolutely resistant to cytotoxic effect of certain 
proapoptogenic molecules, such as TRAIL (Eramo et al., 2005) and TNF. At that, the 
effective destruction of tumor lines by DCs requires the interaction of separate molecules. 
Besides, it is shown that some proapoptogenic molecules could induce the expression of 
receptors for another mediators of apoptosis. Such as, TNFǂ can induce the expression of 
Fas and sensitize glioma cells to FasL/Fas-mediated apoptosis (Weller et al., 1994). 
The further elucidation of the DC cytotoxic/static activity mechanisms and the possible role 
of the defect of DC cytotoxic properties in patients with gliomas as weel as the studies on 
correlation between the antitumor activity of IFNǂ-DCs and clinical outcomes could 
probably explain the different sensitivity of cancer patients to the treatment, and justify new 
immunotherapeutic approaches to the treatment of malignant brain gliomas. 
3. Conclusion 
The capacity of IFNǂ-DCs to lyse tumor cell lines and inhibit their proliferation has been 
investigated. LPS-activated IFNǂ-DCs of healthy donors were shown to have dose-
dependent cytotoxic and cytostatic activity against various tumor lines through the 
induction of apoptosis and arrest of cell cycle. DCs lysed both TRAIL-sensitive (Jurkat cells) 
and TRAIL-resistant (HEp-2) cells, and cytotoxic activity against HEp-2 line was mediated 
through the TNF-TNFR1 pathway. In contrast to healthy donors, DCs of patients with 
malignant glioma failed to inhibit growth, but stimulated proliferation of HEp-2 cells. In 
addition, patient DCs had significantly reduced cytotoxic activity against HEp-2 cells. 
Patients with decreased cytotoxic activity were characterized by significantly lower survival 
since defect of cytotoxic activity was associated with high-grade glioma. The defective 
cytotoxic activity of DCs noted against HEp-2 cells was not revealed against glioblastoma U-
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87 line. The data obtained suggest that defect of antitumor activity of patient DCs may have 
diagnostic and prognostic significance. However, whether IFNǂ-DCs could effectively 
destroy primary glioma cells and does this ability play role in pathogenesis of brain glioma 
remains to be clarified. 
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